Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 1,000 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 1,000 shares of the company’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $22.52, for a total value of $22,520.00. Following the completion of the transaction, the chief financial officer now owns 13,000 shares of the company’s stock, valued at $292,760. The trade was a 7.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Monday, January 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $21.59, for a total value of $70,167.50.
• On Friday, January 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.04, for a total transaction of $25,040.00.
• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.51, for a total transaction of $20,259.00.
• On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.15, for a total transaction of $74,202.50.
• On Wednesday, November 27th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.89, for a total transaction of $130,672.50.

Enliven Therapeutics Stock Performance

Shares of NASDAQ ELVN traded down $0.47 during trading hours on Friday, hitting $22.00. The company’s stock had a trading volume of 188,319 shares, compared to its average volume of 254,889. Enliven Therapeutics, Inc. has a 12 month low of $10.90 and a 12 month high of $30.03. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of -11.58 and a beta of 1.03. The business has a 50-day simple moving average of $22.82 and a 200-day simple moving average of $24.24.

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. lifted its stake in Enliven Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock worth $232,000 after acquiring an additional 3,559 shares during the period. SG Americas Securities LLC bought a new position in Enliven Therapeutics in the 3rd quarter worth $256,000. Verition Fund Management LLC purchased a new stake in shares of Enliven Therapeutics in the 3rd quarter worth about $271,000. The Manufacturers Life Insurance Company bought a new stake in shares of Enliven Therapeutics during the 2nd quarter valued at about $322,000. Finally, Quest Partners LLC increased its position in shares of Enliven Therapeutics by 1,226.4% during the third quarter. Quest Partners LLC now owns 21,117 shares of the company’s stock valued at $539,000 after buying an additional 19,525 shares during the period. 95.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have recently commented on ELVN shares. BTIG Research began coverage on Enliven Therapeutics in a report on Friday, December 13th. They issued a “buy” rating and a $42.00 price objective on the stock. Robert W. Baird lifted their price target on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, November 15th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $38.25.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.